EEG Biofeedback to Improve Memory in Adults With Dementia

NCT01168466 | Completed DMC

• 1 other identifier: QMFFTD
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.

Conditions

Dementia

Keywords

Frontotemporal Lobar Degeneration; EEG Biofeedback; Cerebral oxygenation biofeedback; Frontotemporal Dementia; Peak Alpha Amplitude; Quantitative EEG Assessment

Outcome Measures

Primary Outcomes (2)

• Delis-Kaplan Executive Function System, Behavior Rating Inventory of Executive Function- Adult Version, Integrated Visual and Auditory Continuous Performance Test, Symptom Checklist 90R

  Within two weeks of last session

• EEG amplitude

  decreased slow wave amplitudes from 1-4hz

  within two weeks of last session

Study Arms (2)

Neurofeedback

NO INTERVENTION

Waitlist control group.

QEEG-based Neurofeedback Training

EXPERIMENTAL

A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.

Behavioral: QEEG-based Neurofeedback Training

Interventions

QEEG-based Neurofeedback Training BEHAVIORAL

EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.

Also known as: Neurofeedback

QEEG-based Neurofeedback Training

Eligibility Criteria

• Age: 45 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• FTD Symptoms reported by self or caregiver Significantly abnormal scores on Delis-Kaplan Executive Function System and Behavior Rating Inventory of Executive Function- Adult Version

You may not qualify if:

• years of age
• no one with Axis I dx of Bipolar, Psychosis or active Substance Abuse
• no severe Axis II disorders
• symptoms manifesting within the last 5 years and person is still somewhat independent regarding their ADLs.

Sponsors & Collaborators

• Quietmind Foundation: lead

Study Sites (1)

Quietmind Foundation

Lafayette Hill, Pennsylvania, 19444-1800, United States

Location

MeSH Terms

Conditions

Dementia; Frontotemporal Lobar Degeneration; Frontotemporal Dementia

Interventions

Neurofeedback

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; TDP-43 Proteinopathies; Neurodegenerative Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Biofeedback, Psychology; Mind-Body Therapies; Complementary Therapies; Therapeutics; Behavior Therapy; Psychotherapy; Behavioral Disciplines and Activities; Feedback, Psychological

Study Officials

• Marvin H Berman, Ph.D.

  Quietmind Foundation

  PRINCIPAL INVESTIGATOR

• Jon Frederick, Ph.D.

  Quietmind Foundation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: President

Study Record Dates

• First Submitted: July 21, 2010
• First Posted: July 23, 2010
• Study Start: June 1, 2007
• Primary Completion: June 1, 2008
• Study Completion: June 1, 2008
• Last Updated: April 2, 2018

Record last verified: 2018-03

Locations

US (1)